Brian Oleary, MD
Internal Medicine · Naperville, ILNPI 1295702439
Payments from drug & device makers
Across 118 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$396
- Lilly USA, LLC$255
- Boehringer Ingelheim$230
- AstraZeneca$229
- Pfizer$188
- Novartis$143
- plus $834 from 23 others
What the payments were for
- Food & beverage$2,274100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $396 |
| Lilly USA, LLC | 13 | $255 |
| Boehringer Ingelheim | 9 | $230 |
| AstraZeneca | 13 | $229 |
| Pfizer | 8 | $188 |
| Novartis | 7 | $143 |
| Sumitomo Pharma America, Inc. | 5 | $97 |
| GSK | 4 | $69 |
| Bayer | 2 | $61 |
| Sanara Medtech Inc. | 2 | $58 |
| ERMI LLC | 2 | $54 |
| Lundbeck LLC | 2 | $51 |
| Davol Inc. | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Merck | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Travere Therapeutics, Inc. | 1 | $25 |
| Cala Health, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Biogen | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
How this compares
$2,274 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $140,367 |
| JardianceEmpagliflozin | 95 | $129,275 |
| EliquisApixaban | 95 | $128,524 |
| MounjaroTirzepatide | 78 | $96,527 |
| TrulicityDulaglutide | 24 | $54,737 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $47,891 |
| XareltoRivaroxaban | 32 | $38,022 |
| Tolvaptan | 28 | $33,024 |
| JanuviaSitagliptin Phosphate | 30 | $32,603 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $27,307 |
| MyrbetriqMirabegron | 31 | $27,034 |
| GemtesaVibegron | 25 | $24,209 |
| EntrestoSacubitril/Valsartan | 16 | $15,601 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $15,090 |
| Novolog FlexpenInsulin Aspart | 19 | $14,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $255 | $151,264102 claims |
| Novo NordiskOzempic | $396 | $140,36780 claims |
| Boehringer IngelheimJardiance, Tradjenta | $230 | $140,332109 claims |
| PfizerEliquis | $188 | $128,52495 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $69 | $42,39739 claims |
| Johnson & JohnsonXarelto | $19 | $38,02232 claims |
| MerckJanuvia | $34 | $32,60330 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $97 | $24,20925 claims |
| NovartisEntresto | $143 | $15,60116 claims |
| AstraZenecaBreztri Aerosphere | $229 | $11,29915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Naperville
- Shivani KirilukNaperville$1.1M
- Iffat AhmedNaperville$186K
- Carol WeinbergNaperville$110K
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.